• SPX
  • $5,969.34
  • 0.35 %
  • $20.63
  • DJI
  • $44,296.51
  • 0.97 %
  • $426.16
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $19,003.65
  • 0.16 %
  • $31.23
Arbutus Biopharma Corporation (ABUS) Stock Price, News & Analysis

Arbutus Biopharma Corporation (ABUS) Stock Price, News & Analysis

Currency in USD Disclaimer

$3.51

$0.05

(1.3%)

Day's range
$3.45
Day's range
$3.53
50-day range
$3.42
Day's range
$4.54
  • Country: US
  • ISIN: CA03879J1003
52 wk range
$1.79
Day's range
$4.72
  • CEO: Mr. Michael J. McElhaugh
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -2.18
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (ABUS)
  • Company Arbutus Biopharma Corporation
  • Price $3.51
  • Changes Percentage (1.3%)
  • Change $0.05
  • Day Low $3.45
  • Day High $3.53
  • Year High $4.72

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/27/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $8.50
  • High Stock Price Target $8.50
  • Low Stock Price Target $8.50
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.44
  • Trailing P/E Ratio -7.27
  • Forward P/E Ratio -7.27
  • P/E Growth -7.27
  • Net Income $-72,849,000

Income Statement

Quarterly

Annual

Latest News of ABUS

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Arbutus Biopharma Corporation Frequently Asked Questions

  • What is the Arbutus Biopharma Corporation stock price today?

    Today's price of Arbutus Biopharma Corporation is $3.51 — it has increased by +1.3% in the past 24 hours. Watch Arbutus Biopharma Corporation stock price performance more closely on the chart.

  • Does Arbutus Biopharma Corporation release reports?

    Yes, you can track Arbutus Biopharma Corporation's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Arbutus Biopharma Corporation stock forecast?

    Watch the Arbutus Biopharma Corporation chart and read a more detailed Arbutus Biopharma Corporation stock forecast to see what analysts suggest you do with its shares.

  • What is Arbutus Biopharma Corporation stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Arbutus Biopharma Corporation stock ticker.

  • How to buy Arbutus Biopharma Corporation stocks?

    Like other stocks, ABUS shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Arbutus Biopharma Corporation's EBITDA?

    Arbutus Biopharma Corporation measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Arbutus Biopharma Corporation’s financial statements.

  • What is the Arbutus Biopharma Corporation's net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -4.0157102696, which equates to approximately -401.57%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Arbutus Biopharma Corporation stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Arbutus Biopharma Corporation's financials relevant news, and technical analysis. Arbutus Biopharma Corporation's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Arbutus Biopharma Corporation stock currently indicates a “sell” signal. For more insights, review Arbutus Biopharma Corporation’s technical analysis.

  • A revenue figure for Arbutus Biopharma Corporation for its last quarter?

    Arbutus Biopharma Corporation published it's last quarterly revenues at $1.34 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.